Lanfos250 mg

Lanfos is indicated for the reduction of elevated serum phosphate levels (hyperphosphatemia) in patients with end-stage renal disease (ESRD) who are on dialysis (hemodialysis or peritoneal dialysis). This is an FDA-approved, guideline-supported use.

• Established use: Control of hyperphosphatemia in ESRD patients on dialysis, as part of an overall management plan that also includes dietary phosphate restriction.
• Adjunct role: Lanfos is used as an adjunct to dietary phosphate restriction, not as a replacement for it.

Lanfos does not treat the underlying kidney disease; it works only by reducing absorption of phosphate from food in the gut.

Each chewable tablet or oral powder sachet contains Lanthanum Carbonate as the active ingredient, equivalent to elemental lanthanum, commonly available in strengths of 500 mg, 750 mg, and 1,000 mg (as chewable tablets or oral powder for suspension).

Lanfos is a non-calcium, non-aluminum phosphate-binding agent used in patients with chronic kidney disease who require dialysis. It is available as chewable tablets and as an oral powder that can be mixed with soft food.

Unlike calcium-based binders, Lanfos does not add to a patient's calcium load, and unlike aluminum-based binders, it avoids the risk of aluminum-related toxicity with long-term use.

Lanfos belongs to the class of phosphate-binding agents (non-calcium, non-aluminum phosphate binders), used in the management of hyperphosphatemia in chronic kidney disease.

Lanthanum Carbonate dissociates in the acidic environment of the upper gastrointestinal tract to release lanthanum ions. These ions bind dietary phosphate in the gut, forming highly insoluble lanthanum-phosphate complexes.

• This binding reduces the absorption of dietary phosphate across the gastrointestinal tract.
• Bound phosphate is eliminated in the feces rather than being absorbed into the bloodstream.
• Systemic absorption of lanthanum itself is minimal (less than 0.002% of an oral dose), and what is absorbed is bound to plasma proteins and eliminated mainly via the hepatobiliary route.

Lanthanum Carbonate is not systemically active against phosphate levels through any mechanism other than local gut binding; it does not directly affect renal phosphate handling.

Lanfos chewable tablets must be chewed thoroughly (not swallowed whole) and taken with or immediately after meals. The oral powder form should be mixed with a small amount of soft food and taken right away. Consistent administration with meals is essential for the phosphate-binding effect.

Lanfos can bind to or interfere with the absorption of certain oral medications if taken at the same time. Well-documented interactions include:

• Antacids: Concomitant use with other antacids may cause additive effects on gastric pH; separate administration by at least 2 hours.
• Fluoroquinolone antibiotics (e.g., ciprofloxacin): Lanfos reduces absorption of oral quinolones. Take quinolones at least 1 hour before or 4 hours after Lanfos.
• Levothyroxine: Lanfos may reduce absorption of levothyroxine. Separate dosing by at least 2 hours and monitor thyroid-stimulating hormone (TSH) levels when co-administered or discontinued.

As a general precaution, drugs with a narrow therapeutic index that depend on gastrointestinal absorption should be dosed separately from Lanfos unless specific data indicate otherwise, and levels or clinical effect should be monitored where relevant.

The most common side effects of Lanfos, especially when starting therapy, are gastrointestinal:

• Nausea
• Vomiting
• Abdominal pain or discomfort
• Dyspepsia and constipation

Less common but reported effects include allergic skin reactions and tooth-related injury from improper chewing of tablets. Rare but serious gastrointestinal events (bowel obstruction, perforation, or impaction) have been reported, particularly when tablets are swallowed whole instead of chewed, or in patients with abnormal gastrointestinal anatomy or motility disorders; see Precautions and Warnings and Contraindications.

Lanfos should be used during pregnancy only if clearly needed, and only if the potential benefit justifies the potential risk to the fetus; consult a physician before use. Animal studies have shown developmental effects at high doses, and there are limited human data.

It is not known whether Lanfos passes into breast milk. Because systemic absorption of lanthanum is minimal, but data are limited, a physician should be consulted to weigh the benefits of treatment against any potential risk to a nursing infant before use during breastfeeding.

Lanfos should be used with caution in patients with:

• Gastrointestinal disorders such as bowel obstruction risk factors, prior GI surgery, ulcerative colitis, Crohn's disease, or other conditions predisposing to abnormal GI motility, since serious cases of obstruction, perforation, or impaction have been reported (see Contraindications for absolute obstruction/ileus/impaction contraindication).
• Patients scheduled for abdominal imaging, since Lanfos is radio-opaque and may resemble findings on X-ray.

Tablets must always be chewed completely, not swallowed whole, to reduce the risk of GI complications. Serum phosphate and calcium levels should be monitored periodically during therapy. Lanfos does not treat the underlying kidney disease and is not a substitute for dietary phosphate restriction. Lanfos is not an antibiotic and no antimicrobial stewardship precautions apply.

Overdose of Lanfos would be expected to primarily cause exaggerated gastrointestinal effects such as nausea, vomiting, and headache, since the drug acts locally in the gut with minimal systemic absorption. There is no specific antidote. If overdose is suspected, seek immediate medical attention or contact a poison control center; treatment should be supportive and managed by a physician.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Pediatric Use

Safety and efficacy of Lanfos have not been established in pediatric patients. Because lanthanum has been shown to accumulate in developing bone in juvenile animal studies, with unknown long-term consequences, use in children is not recommended unless specifically directed by a specialist.

Geriatric Use

No overall differences in safety or effectiveness have been reported between elderly and younger adult patients on dialysis, but dose titration should follow the same individualized, phosphate-level-guided approach.

Renal Impairment

Lanfos is specifically indicated for patients with end-stage renal disease on dialysis; it is not indicated for earlier stages of chronic kidney disease not on dialysis.

Hepatic Impairment

Use with caution and appropriate clinical monitoring, as specific dosing data in significant hepatic impairment are limited.

Lanfos is generally used long-term, for as long as the patient remains on dialysis and requires phosphate control, with the dose adjusted periodically based on serum phosphate monitoring. Duration should be determined and reviewed regularly by the treating nephrologist.

Phosphate binder (non-calcium, non-aluminum)

Lanthanum Carbonate works locally within the gastrointestinal tract: after dissociating in gastric acid, lanthanum ions bind dietary phosphate to form insoluble complexes that are excreted in the stool, thereby lowering the amount of phosphate absorbed into the bloodstream.

The safety and efficacy of Lanfos have not been established in pediatric patients. Animal data showing lanthanum deposition in developing bone raise concerns about unknown effects on growth and development in children, so use is generally not recommended in this population outside specialist supervision.